Harvard Apparatus Regenerative Technology Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Junli He
- Full Time Employees
- 8
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 84 October Hill Road Holliston MA United States of America 01746
- IPO Date
- Oct 21, 2013
- CIK
- 0001563665
- Website
- hregen.com
- Similar Companies
- Business
- Harvard Apparatus Regenerative Technology, Inc. (HRGN) operates as a clinical-stage biotechnology company specializing in regenerative medicine approaches for disorders of the gastrointestinal system and other organs affected by cancer, trauma, or birth defects. The company focuses on organ-regeneration technologies intended to repair or replace diseased or damaged tissues, with its lead program centered on esophageal regeneration, including implants designed to treat severe esophageal disease and tissue injuries. Core product offerings encompass regenerative medicine platforms, cell-based therapies, and associated surgical implants and devices intended for organ repair and reconstruction; the pipeline also covers esophageal and related gastrointestinal indications, wound repair, and organ reconstruction technologies. HRGN develops technologies that leverage patient-derived or compatible regenerative approaches to restore function in damaged organs and tissues, aiming to address trauma, birth defects, and post-treatment complications. Headquartered in Boston, Massachusetts, HRGN maintains a strategic focus on translational regenerative programs and early clinical development, seeking to advance scalable regenerative solutions through partnerships, collaborations, and potential license and commercialization arrangements. Founding year and corporate origins trace to its emergence as a biotechnology developer targeting regenerative solutions for gastrointestinal and other organ systems, with ongoing efforts to de-risk, validate, and expand the clinical and regulatory pathway for its lead and pipeline assets. The company operates primarily in the United States, with potential investigations into international collaborators, clinical trial sites, and regulatory engagements across relevant jurisdictions as it progresses toward broader clinical application and potential market entry. HRGN's corporate structure includes relationships with parent or affiliated entities in the regenerative medicine ecosystem, as it pursues strategic alliances, prospective acquisitions, and technology licensing to bolster its product and service offerings in regenerative therapies. Continuous updates reflect new partnerships, pipeline advancements, funding events, and regulatory milestones that shape its growth trajectory and capacity to commercialize regenerative technologies.
Harvard Apparatus Regenerative Technology Announces First Patient Treated with Cellspan Esophageal Implant at Mayo Clinic
Harvard Apparatus Regenerative Technology Collaborates with University of Southern California to Test Treatment for Esophageal Disease
Critical Comparison: Arch Therapeutics (OTCMKTS:ARTH) vs. Biostage (OTCMKTS:BSTG)
Harvard Apparatus Regenerative Technology Announces Strategic Collaboration with Children's Hospital Capital institute of Pediatrics in Beijing, China to Advance Treatment for Esophageal Atresia
Harvard Apparatus Regenerative Technology Appoints Mao Zhang to Board of Directors
Harvard Apparatus Regenerative Technology Announces $5 Million Financing to Continue Clinical Trial
Harvard Apparatus Regenerative Technology Reports First Quarter 2024 Financial Results and Recent Business Highlights
Harvard Apparatus Regenerative Technology Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Business Highlights
Harvard Apparatus Regenerative Technology and the McGowan Institute for Regenerative Medicine at the University of Pittsburgh Establish a Research Collaboration to Study the Repair and Regeneration of the Colon following Colectomy
Harvard Apparatus Regenerative Technology and Renowned Professor/Physician Establish a Collaboration to Repair and Regenerate the Uterus
Harvard Apparatus Regenerative Technology Reports Third Quarter 2023 Financial Results
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q3 2023 Results
Activated University of Michigan as The Second Site for Clinical Trial in Severe Esophageal Disease
Approval of an Orphan Disease Application for its lead product, the Cellspan Esophageal Implant by the European Medicines Agency
Harvard Apparatus Regenerative Technology Reports Second Quarter 2023 Financial Results
Harvard Apparatus Regenerative Technology Schedules Conference Call and Webcast for Q2 2023 Results
Biostage Activated Mayo Clinic as The First Site for Clinical Trial in Severe Esophageal Disease
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
Biostage, Inc. (BSTG) Q3 2022 Earnings Call Transcript
Biostage Schedules Conference Call and Webcast for Q2 2022 Results